# Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

> **NCT03293407** · — · COMPLETED · sponsor: **Bayer** · enrollment: 31 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Iloprost (Ventavis, BAYQ6256)
- **DEVICE:** Breelib nebulizer

## Key facts

- **NCT ID:** NCT03293407
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2019-10-09
- **Final completion:** 2020-01-20
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03293407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03293407, "Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03293407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*